<DOC>
	<DOCNO>NCT00505622</DOCNO>
	<brief_summary>This multicentre , open-label extension study evaluate long-term safety , tolerability , efficacy Perampanel ( E2007 ) adjunctive therapy levodopa treat PD subject motor fluctuation . All subject complete E2007-E044-213 E2007-G000-309 candidate enter extension trial , provide meet inclusion/exclusion criterion complete core study , include final efficacy visit .</brief_summary>
	<brief_title>Evaluation Long-term Safety , Tolerability , Efficacy Perampanel ( E2007 ) Adjunctive Therapy Levodopa Treated Parkinson 's Disease Subjects With Motor Fluctuations</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>INCLUSION CRITERIA : Male female subject idiopathic PD fulfil entry criterion study E2007G000309 E2007E044213 . Subjects must complete core efficacy study include final efficacy follow visit applicable . Subjects mild moderate AEs think related Perampanel ( E2007 ) enter study investigator considers safe . EXCLUSION CRITERIA : 1 . Show evidence clinically significant disease ( i.e. , severe cardiovascular pulmonary disease , bronchial asthma , endocrine disease , history peptic ulcer disease , history myocardial infarction residual atrial nodal ventricular arrhythmia ) , opinion investigator , could affect either patient 's safety conduct study . 2 . Pregnant lactating woman . 3 . Women childbearing potential ( WOCBP ) unless infertile ( include surgically sterile ) practice effective contraception ( e.g. , intrauterine device [ IUD ] barrier method plus hormonal method ) . These subject must negative urine pregnancy test Visit 1 2 indicated entry study . These subject must also willing remain current form contraception duration study . Postmenopausal woman may recruit must amenorrhoeic least 1 year consider nonchild bear potential determined investigator . 4 . Subjects past ( within past 5 year ) present history drug alcohol abuse per Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSM IV ) criterion . 5 . Antipsychotics permit necessary . Subjects may take antidepressant medication , however dose must stable 4 week prior first study visit ( visit inclusion exclusion criterion do patient ) . 6 . Subjects past ( within one year ) present history major depression , suicidal ideation , suicide attempt . 7 . Subjects unstable abnormality hepatic , renal , cardiovascular , respiratory , gastrointestinal , haematological , endocrine , metabolic system might complicate assessment tolerability study medication . 8 . Subjects significantly elevate liver enzyme ( abnormal bilirubin serum transaminase level 1.5 time upper limit normal range ) . 9 . Subjects current prior treatment ( within 4 week prior Screening Visit ) medication know induce enzyme CYP3A4 . 10 . Clinically significant ECG abnormality , and/or prolong QTc ( define QTc â‰¥ 450 msec ) . 11 . Current prior treatment ( within 4 week prior entry visit ) tolcapone , methyldopa , budipine , reserpine . 12 . Subjects previous stereotactic surgery ( e.g. , pallidotomy ) PD plan stereotactic surgery study period 13 . Subjects receive plan ( next 12 month ) deep brain stimulation . 14 . Subjects condition affect peripheral central sensory system unless relate PD ( mild sensory pain syndrome limit OFF period ) could interfere evaluation symptom cause study medication . 15 . Subjects receive investigational product ( E2007 entacapone 200 mg ) within 4 week prior Screening 16 . Any condition could , opinion investigator , place subject increase risk likely prevent completion study . 17 . Subjects condition would make subject , opinion investigator , unsuitable study . 18 . Patients pergolide cabergoline .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>